Xenogenics’ Ideal BioStent™ is the only stent incorporating salicylate, the active component in aspirin, directly into the polymer chain. As the polymer degrades, salicylate is released directly into the vessel wall, thereby providing anti-inflammatory and anti-thrombotic therapy aimed at reducing inflammation and the chance of blood clot formation while promoting blood vessel healing.
Xenogenics also incorporated Sirolimus (rapamycin) in addition to salicylate into the Ideal BioStent™ providing anti-restenotic therapy similar to today’s commonly used drug-eluting metal stents. Xenogenics’ bioabsorbable stent technology allows for the ability to layer different combinations of polymers and drugs, enabling the optimization of the delivery of combination drug therapies to provide superior clinical results. Xenogenics’ Ideal BioStent™ represents a significant advance over currently available stents, including:
The ability to promote positive vessel remodeling.
A significant reduction in late-stent thrombosis risk.
No metal artifact remaining in the patient’s body after vessel healing.
The reduced need for long-term and costly anti-platelet therapy.
